Sandra Ortiz‐Cuaran

2.9k total citations
35 papers, 1.0k citations indexed

About

Sandra Ortiz‐Cuaran is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Sandra Ortiz‐Cuaran has authored 35 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 13 papers in Molecular Biology. Recurrent topics in Sandra Ortiz‐Cuaran's work include Lung Cancer Treatments and Mutations (12 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Cancer Genomics and Diagnostics (9 papers). Sandra Ortiz‐Cuaran is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Cancer Genomics and Diagnostics (9 papers). Sandra Ortiz‐Cuaran collaborates with scholars based in France, United States and Sweden. Sandra Ortiz‐Cuaran's co-authors include Pierre Saintigny, Pierre Savagner, Linda Mahjoubi, Stéphane Terry, Jean Paul Thiery, Salem Chouaı̈b, Pierre Hainaut, Aurélie Swalduz, Doriane Gouas and Hind Hafsi and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Sandra Ortiz‐Cuaran

31 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sandra Ortiz‐Cuaran France 16 527 486 297 208 151 35 1.0k
Samuel J. Vidal United States 7 308 0.6× 473 1.0× 217 0.7× 164 0.8× 73 0.5× 12 798
Benjamin Ruf United States 14 343 0.7× 280 0.6× 146 0.5× 144 0.7× 298 2.0× 29 869
Anliang Xia China 12 469 0.9× 455 0.9× 260 0.9× 106 0.5× 379 2.5× 18 960
Fulin Qiang China 23 349 0.7× 814 1.7× 556 1.9× 126 0.6× 193 1.3× 37 1.3k
Ming-hua Zhu China 21 289 0.5× 833 1.7× 461 1.6× 83 0.4× 100 0.7× 50 1.2k
Yen-An Tang Taiwan 14 299 0.6× 792 1.6× 360 1.2× 104 0.5× 102 0.7× 15 1.0k
Yun Gao China 16 381 0.7× 407 0.8× 248 0.8× 67 0.3× 371 2.5× 33 1.1k
Hyang Sook Seol South Korea 15 288 0.5× 327 0.7× 228 0.8× 98 0.5× 97 0.6× 22 754
Ro Ra Oh South Korea 16 350 0.7× 843 1.7× 245 0.8× 141 0.7× 257 1.7× 16 1.2k

Countries citing papers authored by Sandra Ortiz‐Cuaran

Since Specialization
Citations

This map shows the geographic impact of Sandra Ortiz‐Cuaran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra Ortiz‐Cuaran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra Ortiz‐Cuaran more than expected).

Fields of papers citing papers by Sandra Ortiz‐Cuaran

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandra Ortiz‐Cuaran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra Ortiz‐Cuaran. The network helps show where Sandra Ortiz‐Cuaran may publish in the future.

Co-authorship network of co-authors of Sandra Ortiz‐Cuaran

This figure shows the co-authorship network connecting the top 25 collaborators of Sandra Ortiz‐Cuaran. A scholar is included among the top collaborators of Sandra Ortiz‐Cuaran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandra Ortiz‐Cuaran. Sandra Ortiz‐Cuaran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ortiz‐Cuaran, Sandra, et al.. (2025). Mechanisms of Adaptive Resistance to Targeted Therapy in RET-Aberrant Cancers. Clinical Cancer Research. 31(6). 958–959.
2.
Bouhamama, Amine, Benjamin Leporq, Jean‐Philippe Foy, et al.. (2023). Radiomics combined with transcriptomics to predict response to immunotherapy from patients treated with PD-1/PD-L1 inhibitors for advanced NSCLC. SHILAP Revista de lepidopterología. 3. 1168448–1168448. 5 indexed citations
3.
Lorenz, Carina, Maria Cartolano, Dennis Plenker, et al.. (2023). Characterizing Evolutionary Dynamics Reveals Strategies to Exhaust the Spectrum of Subclonal Resistance in EGFR-Mutant Lung Cancer. Cancer Research. 83(15). 2471–2479. 7 indexed citations
4.
Ortiz‐Cuaran, Sandra, et al.. (2023). Tackling Osimertinib Resistance in EGFR-Mutant Non–Small Cell Lung Cancer. Clinical Cancer Research. 29(18). 3579–3591. 37 indexed citations
5.
Swalduz, Aurélie, et al.. (2022). Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies. Frontiers in Oncology. 12. 796832–796832. 37 indexed citations
6.
Kamga, Paul Takam, Aurélie Swalduz, Adrien Costantini, et al.. (2021). High Circulating Sonic Hedgehog Protein Is Associated With Poor Outcome in EGFR-Mutated Advanced NSCLC Treated With Tyrosine Kinase Inhibitors. Frontiers in Oncology. 11. 747692–747692. 3 indexed citations
7.
Gobbini, Élisa, Aurélie Swalduz, Matteo Giaj Levra, et al.. (2020). Implementing ctDNA Analysis in the Clinic: Challenges and Opportunities in Non-Small Cell Lung Cancer. Cancers. 12(11). 3112–3112. 26 indexed citations
8.
Remón, Jordi, Aurélie Swalduz, David Planchard, et al.. (2020). Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay. PLoS ONE. 15(6). e0234302–e0234302. 14 indexed citations
9.
Jagadeeshan, Sankar, Manu Prasad, Sandra Ortiz‐Cuaran, et al.. (2019). Adaptive Responses to Monotherapy in Head and Neck Cancer: Interventions for Rationale-Based Therapeutic Combinations. Trends in cancer. 5(6). 365–390. 11 indexed citations
10.
Foy, Jean‐Philippe, Chloé Bertolus, Sandra Ortiz‐Cuaran, et al.. (2018). Immunological and classical subtypes of oral premalignant lesions. OncoImmunology. 7(12). e1496880–e1496880. 38 indexed citations
11.
Ortiz‐Cuaran, Sandra, Aurélie Swalduz, Séverine Martinez, et al.. (2018). Abstract 937: Longitudinal circulating-tumor DNA profiling of EGFR-mutated non-small cell lung cancer patients treated with EGFR-tyrosine kinase inhibitors. Cancer Research. 78(13_Supplement). 937–937.
12.
Foy, Jean‐Philippe, Louis Bazire, Sandra Ortiz‐Cuaran, et al.. (2017). A 13-gene expression-based radioresistance score highlights the heterogeneity in the response to radiation therapy across HPV-negative HNSCC molecular subtypes. BMC Medicine. 15(1). 165–165. 35 indexed citations
13.
Richard, Corentin, Jean David Fumet, Sandra Ortiz‐Cuaran, et al.. (2017). Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer. OncoImmunology. 6(9). e1339856–e1339856. 9 indexed citations
14.
Ortiz‐Cuaran, Sandra, Aurélie Swalduz, Christine Ménétrier‐Caux, et al.. (2016). Abstract 2320: CD70 immune checkpoint ligand is associated with the epithelial-to-mesenchymal transition in non-small cell lung cancer. Cancer Research. 76(14_Supplement). 2320–2320. 2 indexed citations
15.
Ortiz‐Cuaran, Sandra, David G. Cox, Stéphanie Villar, et al.. (2013). Association between TP53 R249S mutation and polymorphisms in TP53 intron 1 in hepatocellular carcinoma. Genes Chromosomes and Cancer. 52(10). 912–919. 10 indexed citations
16.
Villar, Stéphanie, Sandra Ortiz‐Cuaran, Behnoush Abedi‐Ardekani, et al.. (2012). Aflatoxin-Induced TP53 R249S Mutation in HepatoCellular Carcinoma in Thailand: Association with Tumors Developing in the Absence of Liver Cirrhosis. PLoS ONE. 7(6). e37707–e37707. 41 indexed citations
17.
Ortiz‐Cuaran, Sandra, Stéphanie Villar, Doriane Gouas, et al.. (2012). Association between HBX status, aflatoxin-induced R249S TP53 mutation and risk of hepatocellular carcinoma in a case-control study from Thailand. Cancer Letters. 331(1). 46–51. 25 indexed citations
18.
Gouas, Doriane, Stéphanie Villar, Sandra Ortiz‐Cuaran, et al.. (2012). TP53 R249S mutation, genetic variations in HBX and risk of hepatocellular carcinoma in The Gambia. Carcinogenesis. 33(6). 1219–1224. 34 indexed citations
19.
Marcel, Virginie, Charlotte Sagne, Hind Hafsi, et al.. (2011). Biological functions of p53 isoforms through evolution: lessons from animal and cellular models. Cell Death and Differentiation. 18(12). 1815–1824. 158 indexed citations
20.
Gouas, Doriane, Hong Shi, A. Hautefeuille, et al.. (2010). Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein. Carcinogenesis. 31(8). 1475–1482. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Samuel J. Vidal Breakdown of academic impact, for papers by Benjamin Ruf Breakdown of academic impact, for papers by Anliang Xia Breakdown of academic impact, for papers by Fulin Qiang Breakdown of academic impact, for papers by Ming-hua Zhu Breakdown of academic impact, for papers by Yen-An Tang Breakdown of academic impact, for papers by Yun Gao Breakdown of academic impact, for papers by Hyang Sook Seol Breakdown of academic impact, for papers by Ro Ra Oh
Rankless by CCL
2026